In vitro assay development and optimization for the prediction of immune-related adverse events following immunotherapy
Cancer immunotherapies activate the immune system to overcome tumor resistance and restore the antitumor immune response, however, excessive activation of the immune system may also affect normal tissues and organs and cause immune-related adverse events (irAEs) of varying severity. Current in vitro assays used for testing and predicting of irAEs induced by immunotherapeutics are associated with s
